|
(DRAAGQPAG)3 (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) control/blocking peptide |
DRAA31-P |
100 ug |
ALPHA DIAGNOSTICS |
|
|
|
|
(DRADGQPAG)3 peptide (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP), pure |
DRAD31-P |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
(NANP)10 (40-aa NANP repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) peptide, pure |
NANP101-P |
0.5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
(NANP)5 peptide (repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) control/blocking peptide |
NANP51-P |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
(NVDP)4 peptide (minor repeat-sequence peptide of the P. falciparum circumsporozoite protein, CSP) control/blocking peptide |
NVDP41-P |
100 ug |
ALPHA DIAGNOSTICS |
|
|
|
|
(PAPPNAAND)3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP), pure |
PAPP311-P |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
(PPPPNAND)3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP) control/blocking peptide |
PPPP321-P |
100 ug |
ALPHA DIAGNOSTICS |
|
|
|
|
(PPPPNPPND)3 peptide (repeat-sequence peptide of the P. berghei circumsporozoite protein, CSP), pure |
PPPP312-P |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
234 CM [Lys-Tyr-Ile-Cys-Asn-Ser-Ser-Cys-Met; MW: 1048.26] |
SP-88259-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
234 CW [Lys-Tyr-Met-Cys-Asn-Ser-Ser-Cys-Met; MW: 1066.30] |
SP-88260-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
26Rfa, Hypothalamic Peptide, frog [Val-Gly-Thr-Ala-Leu-Gly-Ser-Leu-Ala-Glu-Glu-Leu-Asn-Gly-Tyr-Asn-Arg-Lys-Lys-Gly-Gly-Phe-Ser-Phe-Arg-Phe-NH2; MW: 2818.21] |
SP-88343-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
26Rfa, Hypothalamic Peptide, human [Thr-Ser-Gly-Pro-Leu-Gly-Asn-Leu-Ala-Glu-Glu-Leu-Asn-Gly-Tyr-Ser-Arg-Lys-Lys-Gly-Gly-Phe-Ser-Phe-Arg-Phe-NH2; MW: 2832.20] |
SP-67811-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
26Rfa, Hypothalamic Peptide, rat [Ala-Ser-Gly-Pro-Leu-Gly-Thr-Leu-Ala-Glu-Glu-Leu-Ser-Ser-Tyr-Ser-Arg-Arg-Lys-Gly-Gly-Phe-Ser-Phe-Arg-Phe-NH2; MW: 2820.18] |
SP-88344-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
2B-(A) [Biotin-Arg-Arg-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-Ala-Pro-Gln-Leu-OH; MW: 1983.23] |
SP-55157-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
2B-(pS) [Biotin-Arg-Arg-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-Gly-pSer-Pro-Gln-Leu; MW: 2062.22] |
SP-101375-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
2B-(S) [Biotin-Arg-Arg-Ala-Ala-Gly-Gly-Leu-asp-Ser-Arg-Ala-Gly-Ser-Pro-Gln-Leu-OH; MW: 2000.24] |
SP-55158-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
4A/4B, 5A/5B Peptide [Ac-Asp-Glu-Met-Glu-Glu-Cys-Ser-Met-Ser-Tyr-NH2; MW: 1264.38] |
SP-88150-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
4A/4B, Peptide (1) [Asp-Glu-Met-Glu-Glu-Cys-Ser-Gln-His-Leu-Pro-Tyr-Ile; MW: 1593.76] |
SP-88149-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
4B/5A, Peptdie [Glu-Cys-Thr-Thr-Pro-Cys-Ser-Gly-Ser-Trp-Leu-Arg-Asp; MW: 1454.60] |
SP-88151-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
5A/5B, Peptide (1) [Glu-Asp-Val-Val-Abu-Cys-Ser-Met-Ser-Tyr; MW: 1117.24] |
SP-101346-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
5A/5B, Peptide (3) [Ac-Glu-Glu-Val-Val-Ala-Cys-pNA; MW: 810.9] |
SP-101347-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a- Bag Cell Peptide (1 - 8) [Ala-Pro-Arg-Leu-Arg-Phe-Tyr-Ser (MW: 1009.19)] |
SP-88222-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
A-18-F-NH2; Morphine Modulating Neuropeptide [Ala-Gly-Glu-Gly-Leu-Ser-Ser-Pro-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2 (MW: 1920.7)] |
SP-89042-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
A-779 [H-Asp-Arg-Val-Tyr-Ile-His-D-Ala-OH; MW: 872.99] |
SP-55258-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
A-A-A-Y-G-G-F-L [Ala-Ala-Ala-Tyr-Gly-Gly-Phe-Leu (MW: 768.87)] |
SP-88440-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-ANF (1-28), Human [Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cus-Asn-Ser-Phe-Arg-Tyr(Disulfide bridge Cys7-Cys23); MW: 3080.46] |
SP-52223-1 |
0.5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Bag Cell Peptide (1 - 7) [Ala-Pro-Arg-Leu-Arg-Phe-Tyr (MW: 922.11)] |
SP-88221-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Bag Cell Peptide (1 - 9) [Ala-Pro-Arg-Leu-Arg-Phe-Tyr-Ser-Leu (MW: 1122.35)] |
SP-88223-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Casein (90-95) [Arg-Tyr-Leu-Gly-Tyr-Leu (MW: 2367.83)] |
SP-87477-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Casomorphin (1-2) [Tyr-Pro (MW: 278.31)] |
SP-55314-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (19 - 37), human [Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2] |
SP-88241-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (23-37) (human) [Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2 (MW: 1620.89)] |
SP-89401-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (29-37) (canine, mouse, rat) [Pro-Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 (MW: 9200)] |
SP-89403-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (30-37) (canine, mouse, rat) [Thr-Asn-Val-Gly-Ser-Glu-Ala-Phe-NH2 (MW: 822.88)] |
SP-89404-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (31-37) (canine, mouse, rat) [Asn-Val-Gly-Ser-Glu-Ala-Phe- NH2 (MW: 721.77)] |
SP-89405-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (32-37) (canine, mouse, porcine, rat) [Val-Gly-Ser-Glu-Ala-Phe-NH2 (MW: 607.67)] |
SP-89406-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-CGRP (33-37) (canine, mouse, porcine, rat) [Gly-Ser-Glu-Ala-Phe-NH2 (MW: 508.54)] |
SP-87407-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Conotoxin EI (AA: Arg-Asp-Hyp-Cys-Cys-Tyr-His-Pro-Thr-Cys-Asn-Met-Ser-Asn-Pro-Gln-Ile-Cys- NH2) (MW: 2091.39) |
SP-103040-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Conotoxin GS (AA: Ala-Cys-Ser-Gly-Arg-Gly-Ser-Arg-Cys-Hyp-Hyp-Gln-Cys-Cys-Met-Gly-Leu-Arg-Cys-Gly-Arg-Gly-Asn-Pro-Gln-Lys-Cys-Ile-Gly-Ala-His-Gla-Asp-Val) (MW: 3624.11) |
SP-103042-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Conotoxin MI (AA: Gly-Arg-Cys-Cys-His-Pro-Ala-Cys-Gly-Lys-Asn-Tyr-Ser-Cys- NH2) (MW: 1497.74) |
SP-103044-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Conotoxin SI [Ile-Cys-Cys-Asn-Pro-Ala-Cys-Gly-Pro-Lys-Tyr-Ser-Cys- NH2 (Disulfide bridges: Cys2-Cys7, Cys3-Cys13 ) (MW: 1353.6)] |
SP-101853-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Conotoxin SIA (AA: Tyr-Cys-Cys-His-Pro-Ala-Cys-Gly-Lys-Asn-Phe-Asp-Cys-NH2 (Disulfide bridge: Cys2 -Cys7,Cys3 - Cys13)) (MW: 1455.7) |
SP-102111-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Defensin-1, human [Asp-His-Tyr-Asn-Cys-Val-Ser-Ser-Gly-Gly-Gln-Cys-Leu-Tyr-Ser-Ala-Cys-Pro-Ile-Phe-Thr-Lys-Ile-Gln-Gly-Thr-Cys-Tyr-Arg-Gly-Lys-Ala-Lys-Cys-Cys-Lys (Disulfide bridge: Cys5- Cys34, Cy |
SP-88391-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
A-F-A [Ala-Phe-Ala (MW: 307.35)] |
SP-84995-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
A-G-D-V peptide [H-Ala-Gly-Asp-Val-OH; MW: 360.37] |
SP-55170-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Gliadin (57-73) [Gln-Leu-Gln-Pro-Phe-Pro-Gln-Pro-Glu-Leu-Pro-Tyr-Pro-Gln-Pro-Gln-Ser (MW: 1994.25)] |
SP-58780-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Gliadin (57-89) [Ac-LQL QPF PQP ELP YPQ PQL PYP QPQ LPY PQP QPF-NH2; mol wt 3953.5), 33-aa, deamidated antigen for celiac disease |
SP-89924-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
A-H-A [Ala-His-Ala (MW: 297.32)] |
SP-84987-5 |
5 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Helical CRF (12-41) [Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2 (MW: 34978)] |
SP-89540-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|
|
a-Helical CRF (9-41) [Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Met-Leu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-Ala-Glu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Leu-Leu-Glu-Glu-Ala-NH2 (MW: 3826.44)] |
SP-89539-1 |
1 mg |
ALPHA DIAGNOSTICS |
|
|
|